CLEVELAND, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 5:15 pm Eastern. Mr. Petras, Jon Lyons, Senior Vice President and CFO, and Jason Peterson, Vice President and Treasurer, will participate in meetings with investors during the conference.
A live webcast of Mr. Petras’ presentation and accompanying materials may be accessed via the Investor Relations section of the Company’s website at Presentation & Events | Sotera Health. A replay of the webcast will be archived on the Company's website.
About Sotera Health
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company’s website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.
INVESTOR RELATIONS CONTACTS:
Jason Peterson
Vice President & Treasurer, Sotera Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer, Sotera Health
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$11.38 |
Daily Change: | -0.23 -1.98 |
Daily Volume: | 980,028 |
Market Cap: | US$3.230B |
May 01, 2025 March 04, 2025 February 27, 2025 January 14, 2025 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load